Inloggad som:
SEAMARK
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
SEAMARK
A phase 2, randomized, open-label study of Encorafenib and Cetuximab plus Pembrolizumab versus Pembrolizumab alone in participants with previously untreated BRAFV600E-mutant, MSI-H/dMMR metastatic colorectal cancer
A phase 2, randomized, open-label study of Encorafenib and Cetuximab plus Pembrolizumab versus Pembrolizumab alone in participants with previously untreated BRAFV600E-mutant, MSI-H/dMMR metastatic colorectal cancer
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast av: studyjohanna (2023-03-18)